NIH-Funded ACTIV/ACTIV-Associated Clinical Trials

Company Therapeutic Class Administration New/
Repurposed
Status/Estimated
End Date

ACTIV-1 Inpatient

AbbVie Cenicriviroc Immune Modulator Oral New Enrollment Closed
BMS Orencia® (abatacept) Immune Modulator Intravenous Repurposed Enrollment Closed
Janssen Remicade® (Infliximab) Immune Modulator Intravenous Repurposed Enrollment Closed

ACTIV-2 Outpatient

AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intramuscular New Enrollment Closed
AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Enrollment Closed
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Enrollment Closed
Bristol Myers Squibb BMS-986414 and BMS-986413 (also known as C135-LS and C144-LS) Monoclonal Antibody Cocktail Subcutaneous Injection New Enrollment Closed
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Ended
SAB Biotherapeutics SAB-185 Polyclonal antibody Intravenous New Q1 2022
Sagent Camostat Mesylate Antiviral Oral Repurposed Enrollment Closed
Synairgen SNG001 IFN-beta Immune Modulator Inhaled Repurposed Q2 2022

ACTIV-3 Inpatient

AstraZeneca AZD7442 Monoclonal Antibody Cocktail Intravenous New Enrollment Closed
Brii Biosciences Brii-196 & Brii-198 Monoclonal Antibody Cocktail Intravenous New Ended
Eli Lilly LY-CoV-555 Monoclonal Antibody Single Intravenous New Ended
Giliad/NeuroRx ZyesamiTM (aviptadil acetate) and Veklury® (remdesivir)  Immune Modulator/Antiviral Intravenous Repurposed Q1 2022
GSK-Vir VIR-7831 Monoclonal Antibody Single Intravenous New Ended
Molecular Partners/Novartis Ensovibep (MP0420) DARPin Intravenous New Enrollment Closed
Pfizer PF-07304814 Protease inhibitor Intravenous New Q3 2022

ACTIV-4

Outpatients

BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Ended
BMS/Pfizer Aspirin Antiplatelet Oral Repurposed Ended

Inpatients

Other Un-fractionated (UF) Heparin Anticoagulant Intravenous Repurposed Ended
Other Unfractionated Heparin and P2Y12 Inhibitors Anticoagulant Intravenous Repurposed Q3 2021
Other Low Molecular Weight (LMW) Heparin Anticoagulant Injection Repurposed Ended
Other Therapeutic Heparin and P2Y12 Inhibitors Anticoagulant Intravenous and Oral Repurposed Enrollment Closed
Other Prophylactic Heparin and P2Y12 Inhibitors Anticoagulant Intravenous and Oral Repurposed Q2 2022
Novartis Crizanlizumab Monoclonal Antibody Single Intravenous  Repurposed Q1 2023
Various SGLT2i Sodium/glucose cotransporter-2 inhibitors Oral Repurposed Q1 2023

Convalescent

BMS/Pfizer Eliquis ® (apixaban) Anticoagulant Oral Repurposed Q4 2021

Host Tissue

Constant Therapeutics TXA127 Mas Receptor Agonist IV New Q3 2022
Trevena TRV027 AT1R Beta-arrestin Agonist IV New Q3 2022
Rigel Fostamatinib Syk Inhibitor Oral Repurposed Q3/4 2022

ACTIV-5 Inpatient

AbbVie/Boehringer Ingelheim SkyrisiTM (risankizumab) Immune Modulator Intravenous Repurposed Enrollment Closed
Humanigen Lenzilumab Immune Modulator Intravenous New Q4 2021
Alexion Danicopan

Factor D Inhibitor

Oral New Q4 2021

ACTIV-6 Outpatient

Apotex Fluvoxamine Immune Modulator/Antiviral Oral Repurposed Q1 2022
GlaxoSmithKline Fluticasone Immune Modulator Oral Repurposed Q1 2022
Ingenus Ivermectin Immune Modulator/Antiviral Oral Repurposed Q1 2022

ACTIV-Associated

Adaptive COVID-19 Treatment Trial (ACTT) Inpatient

Gilead Veklury® (remdesivir) Antiviral Intravenous Repurposed Ended
Gilead/Eli Lilly Veklury® (remdesivir) and Olumiant® (baricitinib) Antiviral/Anti-Inflammatory Intravenous/Oral Repurposed Ended
Gilead/Merck KGaA Veklury® (remdesivir) and Rebif® (IFN-beta ) Antiviral/Immune Modulator Injection Repurposed Ended
Gilead/Eli Lilly/Other Veklury® (remdesivir) and Olumiant® (baricitinib) or Dexamethasone Antiviral/Anti-Inflammatory/
Immune Modulator
Intravenous/Oral Repurposed Ended

Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)

Gilead/Other Veklury® (remdesivir) and Hyperimmune
Intravenous Immunoglobulin (hIVIG)
Antiviral Intravenous N/A Q3 2021

Convalescent Plasma in Outpatients with COVID-19 (C3PO)

Other Convalescent Plasma Convalescent Plasma Intravenous N/A Ended

Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN COVID-19)

Other Convalescent Plasma Convalescent Plasma Intravenous N/A Q2 2021

Passive Immunity Trial of Our Nation (PassItOn) Inpatient

Other Convalescent Plasma Convalescent Plasma Intravenous N/A Q2 2021

This page last reviewed on January 11, 2022